uniQure investors face April 13 deadline for class action lawsuit

Investors in uniQure, a Dutch biotechnology company specializing in gene therapies, face a critical April 13 deadline to join a class action lawsuit filed in the United States District Court for the District of Delaware, alleging the company made misleading statements about its clinical trial results and financial prospects. The lawsuit, which was initiated following a significant drop in uniQure's stock price, claims that the company failed to adequately disclose negative data from its trials for AMT-130, an experimental treatment for Huntington's disease, leading investors to make uninformed decisions. uniQure, listed on NASDAQ under the symbol QURE, has been developing gene therapies for various rare diseases and has faced increasing scrutiny from investors following several setbacks in its clinical pipeline. The class action lawsuit represents a significant legal challenge for the Amsterdam-based firm, potentially exposing it to substantial financial liabilities if the court rules in favor of the plaintiffs. The company's stock experienced substantial volatility in 2022 and 2023 after reports emerged concerning the efficacy of its lead therapeutic candidates. Legal experts note that biotechnology companies frequently face securities litigation when clinical trial results deviate from expectations, particularly when public statements may have portrayed a more favorable outlook than warranted by the data. The April 13 deadline represents the cutoff for affected investors to participate in the collective legal action, after which only named plaintiffs will continue the litigation.